Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous transplant and maintenance in elderly multiple myeloma
NCT01849783Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, thalidomide, melphalan in multiple myeloma (MM), extramedullary plasmacytoma (EMP), solitary bone plasmacytoma (SBP), light chain deposition disease (LCDD), primary systemic amyloidosis. Started Apr 2013; status: completed.
02
Drugs
bortezomibthalidomidemelphalan
03
Conditions
multiple myeloma (MM)extramedullary plasmacytoma (EMP)solitary bone plasmacytoma (SBP)light chain deposition disease (LCDD)primary systemic amyloidosis
Beyond the preview
Go deeper on NCT01849783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01849783.